Movado Q3 Profit More Than Doubles, Lifts Dividend, FY22 View - Quick Facts

Luxury watch maker Movado Group, Inc. (MOV) reported Tuesday that its third-quarter net income was $31.4 million or $1.33 per share, higher than last year's $14.8 million or $0.63 per share.

Adjusted net income was $32.1 million or $1.36 per share, compared to $16.4 million or $0.70 per share a year ago.

Net sales increased 28.2 percent to $217.7 million from $169.9 million in the prior year.

Total net sales increased 5.9 percent as compared to pre-pandemic third quarter fiscal 2020 with an 8.3 percent increase in U.S. net sales and a 4.1 percent increase in International net sales.

Looking ahead, for fiscal 2022, the company raised its outlook and currently expects net sales in a range of approximately $715 million to $720 million, and earnings per share of approximately $3.35 to $3.45.

The company previously expected full-year sales of $680 million-$695 million and earnings per share between $2.75 and $2.90.

Further, Movado said its Board of Directors approved a 25 percent increase to the regular quarterly cash dividend to $0.25 per share from $0.20 per share. The dividend will be paid on December 17 to
shareholders of record as of the close of business on December 3.

The company also announced that its Board has approved a new share buyback program of up to $50 million of its shares.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
MTD Products Inc. is recalling 1,774 units of walk-behind self-propelled lawn mowers for potential risk of fire hazard, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. The company said the lawn mower can leak fuel when it is stored in the upright (vertical) storage position to pose a fire hazard. Nike Inc. announced its plans to exit the Russian market completely following Russia's ongoing war against Ukraine, reports said. The sportswear major, with more than 100 stores in the country, had suspended operations there in March. Earlier in March, while suspending operations temporarily, the company had said its customers that it couldn't guarantee product shipments. The U.S. Food and Drug Administration unveiled its action plan to advance drug development for rare neurodegenerative diseases, including Amyotrophic Lateral Sclerosis or ALS, in five years. The FDA plans specific actions such as regulatory science initiatives, enhancements to existing programs and new policy initiatives for the purpose. It will use public-private partnerships...
Follow RTT